Abstract:Abstract Introduction: It is common to adjust direct oral anticoagulant (DOAC) dosage individually according to the clinical characteristics and coagulation indexes of patients in clinical practice, but its effectiveness and safety are still controversial. The purpose of this study was to analyze the clinical characteristics and follow-up outcomes of elderly patients who adjusted anticoagulant therapy according to coagulation index. Method: Included were patients who were admitted to the geriatric Department of Peking University First Hospital from January 1, 2016 to December 31, 2021, with indications of anticoagulation therapy, receiving DOAC (Dabigatran, Rivaroxaban) therapy, individualized dose adjustment according to APTT (peak value of 46-60s) or AXA (peak value of 0.5-1.0IU/ml), aged ≥60 years, and complete clinical data. Outpatient or telephone follow-up every three months after discharge until termination or death or end of study (December 31, 2022). The clinical features and follow-up results of Dabigatran 110mg BID group and Dabigatran 110mg QD group, Rivaroxaban 5mg BID group and Rivaroxaban 2.5mg BID group were compared. Result: A total of 388 patients were enrolled, including 145 (35.1%) in the Dabigatrangroup and 243 (58.8%) in the rivaroxaban group. The Dabigatrangroup was divided into the 110mg BID group (85 cases) and the 110mg QD group (60 cases), and patients in the 110mg QD group were older, lighter, and had lower glomerular filtration rate (eGFR). The Rivaroxaban group was divided into the 5mg BID group (134 cases) and the 2.5mg BID group (109 cases), and patients in the 2.5mg BID group were older, weighed less, had lower activity of daily living (ADL) scores, and had lower eGFR. The mean follow-up time was 49.5±23.4 months in the Dabigatrangroup and 32.1±20.1 months in the Rivaroxaban group. Survival analysis of bleeding events, thrombotic events, and death was not significantly different between Dabigatran 110mgBID and 110mgQD and Rivaroxaban 5mgBID and 2.5mgBID groups. Conclusion: The clinical characteristics of patients with individualized low-dose DOAC regimen were as follows: age ≥80 years old, weight ≤60kg, ADL score ≤60 points, HAS-BLED score ≥3 points, eGFR < 60ml/min/1.73m², baseline hemoglobin < 120g/L. There was no significant difference in the incidence of bleeding and thrombotic events between individualized low-dose therapy based on patient clotting indicators and standard therapy.

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults

Predicting Drug-Drug Interactions with Physiologically Based Pharmacokinetic/pharmacodynamic Modelling and Optimal Dosing of Apixaban and Rivaroxaban with Dronedarone Co-Administration

Predicting drug-drug interaction with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration

Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation

Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients

Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population

Stroke Prevention Using Dabigatran in Elderly Chinese Patients with Atrial Fibrillation

Clinical Features and Follow-up Outcomes of Individualized Low-dose DOAC Therapy in Chinese Patients Aged 60 Years and Older: A Single-center Study

Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation

Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review

Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation

Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis

Predicting Drug-Drug Interaction with Physiologically Based Pharmacokinetic/Pharmacodynamic Modelling and Optimal Dosing of Oral Anti-Coagulants with Dronedarone Co-Administration

Prevalence, Risk Factors, and Prediction of Inappropriate Use of Non-Vitamin K Antagonist Oral Anticoagulants in Elderly Chinese Patients with Atrial Fibrillation: A Study Protocol

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation

Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice

Drug-drug interactions and the risk of adverse drug reaction-related hospital admissions in the older population

Inappropriate Dosing of Direct Oral Anticoagulants Among Very Elderly Inpatients With Atrial Fibrillation

Potential Herb–drug Interactions in Community-Dwelling Older Adults in China: the Shanghai Aging Study